Review Article the Tendency of Malignant Transformation of Mesenchymal Stem Cells in the Inflammatory Microenvironment, Tafs Or Tscs?
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
The Interactions of DNA Repair, Telomere Homeostasis, and P53 Mutational Status in Solid Cancers: Risk, Prognosis, and Prediction
cancers Review The Interactions of DNA Repair, Telomere Homeostasis, and p53 Mutational Status in Solid Cancers: Risk, Prognosis, and Prediction Pavel Vodicka 1,2,3, Ladislav Andera 4,5, Alena Opattova 1,2,3,† and Ludmila Vodickova 1,2,3,*,† 1 Institute of Experimental Medicine, AS CR, 142 20 Prague, Czech Republic; [email protected] (P.V.); [email protected] (A.O.) 2 First Medical Faculty, Charles University, 121 08 Prague, Czech Republic 3 Biomedical Center, Faculty of Medicine in Pilsen, Charles University, 301 00 Pilsen, Czech Republic 4 Institute of Biotechnology, AS CR, 252 50 Vestec, Czech Republic; [email protected] 5 Institute of Molecular Genetics, AS CR, 142 20 Prague, Czech Republic * Correspondence: [email protected] † These authors contribured eaqually to this paper. Simple Summary: p53 is a nuclear transcription factor with a pro-apoptotic function. Somatic mutations in this gene represent one of the most critical events in human carcinogenesis. The disruption of genomic integrity due to the accumulation of various kinds of DNA damage, deficient DNA repair capacity, and alteration of telomere homeostasis constitute the hallmarks of malignant diseases. The main aim of our review was to accentuate a complex comprehension of the interactions between fundamental players in carcinogenesis of solid malignancies such as DNA damage response, telomere homeostasis and TP53. Abstract: The disruption of genomic integrity due to the accumulation of various kinds of DNA Citation: Vodicka, P.; Andera, L.; Opattova, A.; Vodickova, L. The damage, deficient DNA repair capacity, and telomere shortening constitute the hallmarks of malig- Interactions of DNA Repair, Telomere nant diseases. -
Cadmium Induced Cell Apoptosis, DNA Damage, De
Int. J. Med. Sci. 2013, Vol. 10 1485 Ivyspring International Publisher International Journal of Medical Sciences 2013; 10(11):1485-1496. doi: 10.7150/ijms.6308 Research Paper Cadmium Induced Cell Apoptosis, DNA Damage, De- creased DNA Repair Capacity, and Genomic Instability during Malignant Transformation of Human Bronchial Epithelial Cells Zhiheng Zhou1*, Caixia Wang2*, Haibai Liu1, Qinhai Huang1, Min Wang1 , Yixiong Lei1 1. School of public health, Guangzhou Medical University, Guangzhou 510182, People’s Republic of China 2. Department of internal medicine of Guangzhou First People’s Hospital affiliated to Guangzhou Medical University, Guangzhou 510180, People’s Republic of China * These authors contributed equally to this work. Corresponding author: Yixiong Lei, School of public health, Guangzhou Medical University, 195 Dongfengxi Road, Guangzhou 510182, People’s Republic of China. Fax: +86-20-81340196. E-mail: [email protected] © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. Received: 2013.03.23; Accepted: 2013.08.12; Published: 2013.08.30 Abstract Cadmium and its compounds are well-known human carcinogens, but the mechanisms underlying the carcinogenesis are not entirely understood. Our study was designed to elucidate the mech- anisms of DNA damage in cadmium-induced malignant transformation of human bronchial epi- thelial cells. We analyzed cell cycle, apoptosis, DNA damage, gene expression, genomic instability, and the sequence of exons in DNA repair genes in several kinds of cells. -
Transcriptional Repression of IFN Regulatory Factor 7 by MYC Is Critical for Type I IFN Production in Human Plasmacytoid Dendrit
Transcriptional Repression of IFN Regulatory Factor 7 by MYC Is Critical for Type I IFN Production in Human Plasmacytoid Dendritic Cells This information is current as of September 28, 2021. Tae Whan Kim, Seunghee Hong, Yin Lin, Elise Murat, HyeMee Joo, Taeil Kim, Virginia Pascual and Yong-Jun Liu J Immunol 2016; 197:3348-3359; Prepublished online 14 September 2016; doi: 10.4049/jimmunol.1502385 Downloaded from http://www.jimmunol.org/content/197/8/3348 Supplementary http://www.jimmunol.org/content/suppl/2016/09/14/jimmunol.150238 http://www.jimmunol.org/ Material 5.DCSupplemental References This article cites 74 articles, 25 of which you can access for free at: http://www.jimmunol.org/content/197/8/3348.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 28, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Transcriptional Repression of IFN Regulatory Factor 7 by MYC Is Critical for Type I IFN Production in Human Plasmacytoid Dendritic Cells Tae Whan Kim,*,1 Seunghee Hong,*,1 Yin Lin,* Elise Murat,* HyeMee Joo,* Taeil Kim,†,2 Virginia Pascual,* and Yong-Jun Liu*,† Type I IFNs are crucial mediators of human innate and adaptive immunity and are massively produced from plasmacytoid dendritic cells (pDCs). -
Interferon-Α Therapy in Bcr-Abl-Negative Myeloproliferative Neoplasms
Leukemia (2008) 22, 1990–1998 & 2008 Macmillan Publishers Limited All rights reserved 0887-6924/08 $32.00 www.nature.com/leu SPOTLIGHT REVIEW Interferon-a therapy in bcr-abl-negative myeloproliferative neoplasms J-J Kiladjian1,2,3, C Chomienne4 and P Fenaux1 1Assistance PubliqueFHoˆpitaux de Paris, Hoˆpital Avicenne, Service d’He´matologie Clinique, Bobigny, France; 2Assistance PubliqueFHoˆpitaux de Paris, Hoˆpital Saint-Louis, Centre d’Investigation Clinique, Paris, France; 3Universite´ Paris 7, Denis Diderot, Paris, France and 4Assistance PubliqueFHoˆpitaux de Paris, Hoˆpital Saint-Louis, Unite´ de Biologie Cellulaire, Paris, France Interferon (IFN) was the first cytokine discovered 50 years ago, however, did not allow complete purity, and although leukocyte with a wide range of biological properties, including immuno- IFN consisted predominantly of IFN-a, small amounts of other modulatory, proapoptotic and antiangiogenic activities, that rapidly raised interest in its therapeutic use in malignancies. IFN species were also present. Later on, the cloning of IFN-receptor characterization was also pivotal in the discovery recombinant human IFN-a and -b in 1980 allowed the SPOTLIGHT of the JAK/STAT signaling pathway. Among the large IFN production of large amounts of IFN for characterization, family, mainly one of the type I IFN, IFN-a2, is used in therapy. biological activity studies and clinical trials.5–7 It is only 20 Many clinical trials have shown remarkable efficacy of IFN-a in years after their discovery that two IFN species, IFN-a and -b, bcr-abl-negative myeloproliferative neoplasms (MPNs), espe- could be purified satisfactorily using high-performance liquid cially polycythemia vera (PV), and essential thrombocythemia 8 (ET). -
Herpes Simplex Virus Type 2: Bystander Or Active Player in Cervical Carcinogenesis?
Journal of Gynecology and Women’s Health ISSN 2474-7602 Mini Review J Gynecol Women’s Health Volume 12 Issue 2 - October 2018 Copyright © All rights are reserved by Jude Ogechukwu Okoye DOI: 10.19080/JGWH.2018.12.555832 Herpes Simplex Virus Type 2: Bystander or Active Player in Cervical Carcinogenesis? Jude Ogechukwu Okoye* Department of Medical Laboratory Science, Babcock University, Nigeria Submission: September 19, 2018 ; Published: October 05, 2018 *Corresponding author: Jude Ogechukwu Okoye, Department of Medical Laboratory Science, Babcock University, Nigeria, Tel: ; Email: Abstract More emphasis have been placed on producing vaccines that prevent host cell entry by Human Papillomavirus (HPV) while less attention andhas beenits potential given to to Herpes up-modulate Simplex both virus HPV type regulatory 2 (HSV-2) andwhich oncogenic potentially gene promotes and downregulate acquisition hostand co-habitationtumour suppressor of human suggest immunodeficiency that it is not a virus (HIV), HPV and Epstein-Barr virus (EBV). The tendency for HSV-2 to induce ulcerations and chronic inflammation following reactivation, to reduce cervical cancer related mortality. bystander in cervical carcinogenesis. Thus, efforts geared towards finding HSV-2 effective microbicide and vaccine should be intensified so as Keywords: Herpes Simplex virus type 2; Human papillomavirus; Epstein-Barr virus; Cervical cancer Abbreviations: HPV: Human Papillomavirus; HIV: Human Immune virus; SSC: Squamous Cell Carcinoma; LMP1: Latent Membrane Protein 1; EBV: Epstein-Barr virus; CIN: Cervical Intraepithelial Neoplasia Introduction Cervical cancer is the second most common type of cancer in a woman’s lifetime and may also facilitate EBV infection, a (9.8%) affecting women worldwide [1-3]. -
Type I Interferons in Anticancer Immunity
REVIEWS Type I interferons in anticancer immunity Laurence Zitvogel1–4*, Lorenzo Galluzzi1,5–8*, Oliver Kepp5–9, Mark J. Smyth10,11 and Guido Kroemer5–9,12 Abstract | Type I interferons (IFNs) are known for their key role in antiviral immune responses. In this Review, we discuss accumulating evidence indicating that type I IFNs produced by malignant cells or tumour-infiltrating dendritic cells also control the autocrine or paracrine circuits that underlie cancer immunosurveillance. Many conventional chemotherapeutics, targeted anticancer agents, immunological adjuvants and oncolytic 1Gustave Roussy Cancer Campus, F-94800 Villejuif, viruses are only fully efficient in the presence of intact type I IFN signalling. Moreover, the France. intratumoural expression levels of type I IFNs or of IFN-stimulated genes correlate with 2INSERM, U1015, F-94800 Villejuif, France. favourable disease outcome in several cohorts of patients with cancer. Finally, new 3Université Paris Sud/Paris XI, anticancer immunotherapies are being developed that are based on recombinant type I IFNs, Faculté de Médecine, F-94270 Le Kremlin Bicêtre, France. type I IFN-encoding vectors and type I IFN-expressing cells. 4Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, F-94800 Villejuif, France. Type I interferons (IFNs) were first discovered more than Type I IFNs in cancer immunosurveillance 5Equipe 11 labellisée par la half a century ago as the factors underlying viral inter Type I IFNs are known to mediate antineoplastic effects Ligue Nationale contre le ference — that is, the ability of a primary viral infection against several malignancies, which is a clinically rel Cancer, Centre de Recherche 1 des Cordeliers, F-75006 Paris, to render cells resistant to a second distinct virus . -
Heatmaps - the Gene Expression Edition
Heatmaps - the gene expression edition Jeff Oliver 20 July, 2020 An application of heatmap visualization to investigate differential gene expression. Learning objectives 1. Manipulate data into a ‘tidy’ format 2. Visualize data in a heatmap 3. Become familiar with ggplot syntax for customizing plots Heatmaps for differential gene expression Heatmaps are a great way of displaying three-dimensional data in only two dimensions. But how can we easily translate tabular data into a format for heatmap plotting? By taking advantage of “data munging” and graphics packages, heatmaps are relatively easy to produce in R. Getting started We are going to start by isolating different types of information by imposing structure in our file managment. That is, we are going to put our input data in one folder and any output such as plots or analytical results in a different folder. We can use the dir.create to create these two folders: dir.create("data") dir.create("output") For this lesson, we will use a subset of data on a study of gene expression in cells infected with the influenza virus (doi: 10.4049/jimmunol.1501557). The study infected human plasmacytoid dendritic cells with the influenza virus, and compared gene expression in those cells to gene expression in uninfected cells. Thegoal was to see how the flu virus affected the function of these immune system cells. The data for this lesson is available at: http://tinyurl.com/flu-expression-data or https://jcoliver.github.io/ learn-r/data/GSE68849-expression.csv. Download this comma separated file and put it in the data folder. -
Malignant Transformation of Human Fibroblasts Caused by Expression Of
Proc. Nati. Acad. Sci. USA Vol. 86, pp. 187-191, January 1989 Cell Biology Malignant transformation of human fibroblasts caused by expression of a transfected T24 HRAS oncogene (human cell transformation/infinite life-span human flbroblasts/pHO6T1/T24 HRAS expression/malignant fibrosarcoma) PETER J. HURLIN*, VERONICA M. MAHER, AND J. JUSTIN MCCORMICKt Carcinogenesis Laboratory, Fee Hall, Department of Microbiology and Department of Biochemistry, Michigan State University, East Lansing, MI 48824-1316 Communicated by G. N. Wogan, September 19, 1988 ABSTRACT We showed previously that diploid human passage rodent cells were transfected with an HRAS onco- fibroblasts that express a transfected HRAS oncogene from the gene and any one of a number of genes considered to be human bladder carcinoma cell line T24 exhibit several char- involved in causing cellular immortalization, malignant trans- acteristics of transformed cells but do not acquire an infinite formation resulted (5-7). Not surprisingly, transfection of life-span and are not tumorigenic. To extend these studies ofthe HRAS oncogenes into infinite life-span rodent fibroblast cell T24 HRAS in human cells, we have utilized an infinite life-span, lines resulted in malignant transformation (5, 8) in the but otherwise phenotypically normal, human fibroblast cell majority of the studies (9). strain, MSU-1.1, developed in this laboratory after transfec- To test models proposed for ras transformation generated tion of diploid fibroblasts with a viral v-myc oncogene. Trans- from experiments with rodent fibroblasts for their relevance fection of MSU-1.1 cells with the T24 HRAS flanked by two to human cell transformation, we and our colleagues (10-12) transcriptional enhancer elements (pHO6T1) yielded foci of and several other groups (13-21) have used human fibroblasts morphologically transformed cells. -
The RNA Helicase a in Malignant Transformation
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 19 The RNA helicase A in malignant transformation Marco Fidaleo1,2, Elisa De Paola1,2 and Maria Paola Paronetto1,2 1 Department of Movement, Human and Health Sciences, University of Rome “Foro Italico”, Rome, Italy 2 Laboratory of Cellular and Molecular Neurobiology, CERC, Fondazione Santa Lucia, Rome, Italy Correspondence to: Maria Paola Paronetto, email: [email protected] Keywords: RHA helicase, genomic stability, cancer Received: October 02, 2015 Accepted: January 29, 2016 Published: February 14, 2016 ABSTRACT The RNA helicase A (RHA) is involved in several steps of RNA metabolism, such as RNA processing, cellular transit of viral molecules, ribosome assembly, regulation of transcription and translation of specific mRNAs. RHA is a multifunctional protein whose roles depend on the specific interaction with different molecular partners, which have been extensively characterized in physiological situations. More recently, the functional implication of RHA in human cancer has emerged. Interestingly, RHA was shown to cooperate with both tumor suppressors and oncoproteins in different tumours, indicating that its specific role in cancer is strongly influenced by the cellular context. For instance, silencing of RHA and/or disruption of its interaction with the oncoprotein EWS-FLI1 rendered Ewing sarcoma cells more sensitive to genotoxic stresses and affected tumor growth and maintenance, suggesting possible therapeutic implications. Herein, we review the recent advances in the cellular functions of RHA and discuss its implication in oncogenesis, providing a perspective for future studies and potential translational opportunities in human cancer. INTRODUCTION females, which contain two X chromosomes [8]. The C. elegans RHA-1 displays about 60% of similarity with both RNA helicase A (RHA) is a DNA/RNA helicase human RHA and Drosophila MLE and is involved in gene involved in all the essential steps of RNA metabolism, silencing. -
Origin of Genome Instability and Determinants of Mutational Landscape in Cancer Cells
G C A T T A C G G C A T genes Review Origin of Genome Instability and Determinants of Mutational Landscape in Cancer Cells Sonam Mehrotra * and Indraneel Mittra Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai 410210, India; [email protected] * Correspondence: [email protected]; Tel.: +91-22-27405143 Received: 15 August 2020; Accepted: 18 September 2020; Published: 21 September 2020 Abstract: Genome instability is a crucial and early event associated with an increased predisposition to tumor formation. In the absence of any exogenous agent, a single human cell is subjected to about 70,000 DNA lesions each day. It has now been shown that physiological cellular processes including DNA transactions during DNA replication and transcription contribute to DNA damage and induce DNA damage responses in the cell. These processes are also influenced by the three dimensional-chromatin architecture and epigenetic regulation which are altered during the malignant transformation of cells. In this review, we have discussed recent insights about how replication stress, oncogene activation, chromatin dynamics, and the illegitimate recombination of cell-free chromatin particles deregulate cellular processes in cancer cells and contribute to their evolution. The characterization of such endogenous sources of genome instability in cancer cells can be exploited for the development of new biomarkers and more effective therapies for cancer treatment. Keywords: genome instability; replication stress; replication-transcription conflict; cell free chromatin; cancer 1. Introduction Genome instability is a characteristic feature observed in most human cancers. The accumulation of genetic alterations ranging from single nucleotide mutations to chromosome rearrangements can predispose cells towards malignancy. -
Hyper Telomere Recombination Accelerates Replicative Senescence and May Promote Premature Aging
Hyper telomere recombination accelerates replicative senescence and may promote premature aging R. Tanner Hagelstroma,b, Krastan B. Blagoevc,d, Laura J. Niedernhofere, Edwin H. Goodwinf, and Susan M. Baileya,1 aDepartment of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, CO 80523-1618; bPharmaceutical Genomics Division, Translational Genomics Research Institute, Phoenix, AZ 85004; cNational Science Foundation, Arlington, VA 22230; dDepartment of Physics Cavendish Laboratory, Cambridge University, Cambridge CB3 0HE, United Kingdom; eDepartment of Microbiology and Molecular Genetics, University of Pittsburgh, School of Medicine and Cancer Institute, Pittsburgh, PA 15261; and fKromaTiD Inc., Fort Collins, CO 80524 Edited* by José N. Onuchic, University of California San Diego, La Jolla, CA, and approved August 3, 2010 (received for review May 7, 2010) Werner syndrome and Bloom syndrome result from defects in the cell-cycle arrest known as senescence (12). Most human tissues lack RecQ helicases Werner (WRN) and Bloom (BLM), respectively, and sufficient telomerase activity to maintain telomere length through- display premature aging phenotypes. Similarly, XFE progeroid out life, limiting cell division potential. The majority of cancers syndrome results from defects in the ERCC1-XPF DNA repair endo- circumvent this tumor-suppressor mechanism by reactivating telo- nuclease. To gain insight into the origin of cellular senescence and merase (13), thus removing telomere shortening as a barrier to human aging, we analyzed the dependence of sister chromatid continuous proliferation. In some situations, a recombination- exchange (SCE) frequencies on location [i.e., genomic (G-SCE) vs. telo- based mechanism known as “alternative lengthening of telomeres” meric (T-SCE) DNA] in primary human fibroblasts deficient in WRN, (ALT) maintains telomere length in the absence of telomerase (14). -
Cancer Patients Have a Higher Risk Regarding COVID-19–And Vice Versa?
pharmaceuticals Opinion Cancer Patients Have a Higher Risk Regarding COVID-19–and Vice Versa? Franz Geisslinger, Angelika M. Vollmar and Karin Bartel * Pharmaceutical Biology, Department Pharmacy, Ludwig-Maximilians-University of Munich, 81377 Munich, Germany; [email protected] (F.G.); [email protected] (A.M.V.) * Correspondence: [email protected] Received: 29 May 2020; Accepted: 3 July 2020; Published: 6 July 2020 Abstract: The world is currently suffering from a pandemic which has claimed the lives of over 230,000 people to date. The responsible virus is called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and causes the coronavirus disease 2019 (COVID-19), which is mainly characterized by fever, cough and shortness of breath. In severe cases, the disease can lead to respiratory distress syndrome and septic shock, which are mostly fatal for the patient. The severity of disease progression was hypothesized to be related to an overshooting immune response and was correlated with age and comorbidities, including cancer. A lot of research has lately been focused on the pathogenesis and acute consequences of COVID-19. However, the possibility of long-term consequences caused by viral infections which has been shown for other viruses are not to be neglected. In this regard, this opinion discusses the interplay of SARS-CoV-2 infection and cancer with special focus on the inflammatory immune response and tissue damage caused by infection. We summarize the available literature on COVID-19 suggesting an increased risk for severe disease progression in cancer patients, and we discuss the possibility that SARS-CoV-2 could contribute to cancer development.